Amgen sees potential for Horizon to close by mid-December under court schedule

• Amgen (NASDAQ:AMGN) agreed not to close its $28 billion purchase of Horizon Therapeutics (NASDAQ:HZNP) before Oct. 31 or the second business day after the court rules on the Federal Trade Commission's request to block the deal.
• On Friday, the Chicago court overseeing the case issued an order granting the revised stipulated temporary restraining order, according to an 8-K filing on Monday.
• Horizon (HZNP) expects that its planned sale to Amgen (AMGN) can close by mid-December if a request for a preliminary injunction is denied by the federal court, according to the filing.
• Last month, U.S. District Judge John Kness set a hearing for Sept. 11 on the FTC's efforts to block the combination.

More on Horizon Therapeutics, Amgen

• Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
• FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics
• Amgen agrees not to close Horizon deal before Sept. 15 in court agreement with FTC